Nasdaq-listed biotech firm Sonnet BioTherapeutics announced Monday a $888 million merger agreement with Rorschach I LLC, an ...

Compare plans for Claude Code in this pricing and features breakdown. Discover which plan fits your needs and budget, this in ...

Sonnet BioTherapeutics (NASDAQ:SONN) saw its stock soar by 290% after announcing an $888 million business combination that will pivot the company into a cryptocurrency treasury focused on HYPE tokens.

Sonnet BioTherapeutics enters into an agreement to transform into the largest U.S.-based publicly listed company to hold HYPE ...

Sonnet BioTherapeutics pivots to crypto with $888M deal, forming Hyperliquid Strategies Inc. to hold 12.6M HYPE tokens.

Internal docs show xAI paid contractors to "hillclimb" Grok's rank on a coding leaderboard above Anthropic's Claude.

Sonnet BioTherapeutics will transform into a new entity called HyperLiquid Strategies at the agreement's close. The new company is expected to hold 12.6 million HYPE tokens and gross cash invested of ...

Sonnet to merge with crypto-backed firm, forming Hyperliquid Strategies with $888 million in assets, plus HYPE blockchain ...

The $20/month Claude 4 Opus failed to beat its free sibling, Claude 4 Sonnet, in head-to-head testing. Here's how Sonnet quietly crushed expectations with smarter, safer code.

Sonnet's Echo 13 Thunderbolt 5 SSD Dock includes an incredibly fast SSD inside it that beats most external drives. But it's also a stable, powerful docking station in its own right.

Claude 3.5 Sonnet was able to solve 64% of problems related to bug fixing and functionality additions with open source codebases, a significant improvement over Claude 3 Opus’ 38% success rate.